In the Claims:

Please cancel claims 9-11 and 13. Please amend claims 1-8 and 12 as follows. Please add new claims 14-18.

1. (Currently Amended) A compound of formula (I)



(I)

wherein

R ~~represents~~ is halogen, C_{1-4} alkyl, cyano, C_{1-4} alkoxy, trifluoromethyl or trifluoromethoxy;

R_1 ~~represents~~ is a 5 or 6 membered heteroaryl group, in which the 5-membered heteroaryl group contains at least one heteroatom selected from oxygen, sulphur or nitrogen and the 6-membered heteroaryl group contains from 1 to 3 nitrogen atoms, or R_1 ~~represents~~ is a 4, 5 or 6 membered heterocyclic group, wherein said ~~saids~~ 5 or 6 membered heteroaryl or the 4, 5 or 6 membered heterocyclic group may optionally be substituted by one to three substituents, which may be the same or different, selected from $(CH_2)_pR_6$, wherein p is zero or an integer from 1 to 4 and R_6 is selected from:

halogen,

C_{1-4}alkoxy,

C_{1-4}alkyl,

C_{3-7}cycloalkyl,

C_{1-4} alkyl optionally substituted by halogen, cyano or C_{1-4} alkoxy,

hydroxy,

cyano,

nitro,
trifluoromethyl,
carboxy,
$NH(C_{1-4}$ alkyl),
$N(C_{1-4}$ alkyl$)_2$
$NH(C_{3-7}$ cycloalkyl),
$N(C_{1-4}$ alkyl$)(C_{3-7}$ cycloalkyl);
$NH(C_{1-4}$alkylOC_{1-4}alkoxy),
$OC(O)NR_7R_8$,
$NR_8C(O)$ R_7 or
$C(O)NR_7R_8$;

R_2 ~~represents~~ is hydrogen, or C_{1-4} alkyl ;

R_3 and R_4 independently ~~represents~~ are hydrogen, C_{1-4} alkyl or R_3 together with R_4 and the carbon to which they are bonded is ~~represents~~ C_{3-7} cycloalkyl;

R_5 ~~represents~~ is trifluoromethyl, $S(O)_qC_{1-4}$ alkyl, C_{1-4} alkyl, C_{1-4} alkoxy, trifluoromethoxy, halogen or cyano;

R_7 and R_8 independently ~~represents~~ are hydrogen, C_{1-4} alkyl or C_{3-7} cycloalkyl;

L is a single or a double bond;

n is an integer from 1 to 3;

m is zero or an integer from 1 to 3;

q is zero or an integer from 1 to 2;

provided that

a) when L is a double bond, R_1 is not an optionally substituted 5 or 6 membered heteroaryl group, in which the 5-membered heteroaryl group contains at least one heteroatom selected from oxygen, sulphur or nitrogen and the 6-membered heteroaryl group contains from 1 to 3 nitrogen atoms;

b) the group R_1 is linked to the carbon atom shown as * via a carbon atom;

and

c) when the heteroatom contained in the group R_1 is substituted, p is not zero;

and pharmaceutically acceptable salts and solvates thereof.

2. (Currently Amended) A compound as claimed in claim 1 wherein R is halogen ~~(e.g. fluorine or chlorine)~~ ~~and/~~or ~~a~~ C_{1-4} alkyl ~~(e.g. methyl) group~~ and n is an integer from 1 to 2.

3. (Currently Amended) A compound as claimed in claim 1 ~~or claim 2~~ wherein R_5 is trifluoromethyl, methyl, methoxy, bromine, chlorine or fluorine atom and m is an integer from 1 to 2.

4. (Currently Amended) A compound as claimed in claim 1 ~~any of claims 1 to 3~~ wherein R_1 is piperidyl, morpholinyl, 1,2,3,6-tetrahydro-4-pyridinyl, pyridyl or pyrrolidinyl.

5. (Currently Amended) A compound as claimed in claim 1 ~~any of claims 1 to 4~~ wherein R is halogen ~~(e.g. fluorine or chlorine) and/~~or ~~a~~ C_{1-4} alkyl ~~(e.g. methyl) group~~ and n is an integer from 1 to 2; R_1 is piperidyl, 2-morpholinyl, 1,2,3,6-tetrahydro-4-pyridinyl, pyridyl or pyrrolidinyl and wherein R_1 is optionally substituted by one or two groups selected from halogen ~~(e.g fluorine)~~, C_{1-4} alkyl ~~(e.g. methyl)~~ or ethylC_{1-4} alkoxy; R_2 and R_3 are independently hydrogen or methyl; R_4 is hydrogen, methyl or together with R_3 is cyclopropyl and R_5 is trifluoromethyl, methyl, methoxy, bromine, chlorine or fluorine atom and m is preferably an integer from 1 to 2.

6. (Currently Amended) A compound selected from:

N-(3,5-Bis-trifluoromethyl-benzyl)-3-(4-fluoro-phenyl)-*N*-methyl-3-piperidin-4-yl-propionamide;

N-(3,5-Dichloro-benzyl)-3-(4-fluoro-phenyl)-*N*-methyl-3-piperidin-4-yl-propionamide;

N-[1-(3,5-Dichloro-phenyl)-ethyl]-3-(4-fluoro-phenyl)-*N*-methyl-3-piperidin-4-yl-propionamide;

N-[1-(3,5-Dichloro-phenyl)-ethyl]-3-(4-fluoro-phenyl)-*N*-methyl-3-[1-(2-methoxyethyl)-piperidin-4-yl]-propionamide;

N-(3,5-Dichloro-benzyl)-3-(4-fluoro-phenyl)-3-(4-fluoro-piperidin-4-yl)-*N*-methyl-proprionamide;

N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-*N*-methyl-3-{1-[2-(methyloxy)ethyl]-4-piperidinyl}propionamide*N*-{-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinyl)propanamide;

N-{1-[3,5-bis(trifluoromethyl)phenyl]-1-methylethyl}-3-(4-fluorophenyl)-3-(4-piperidinyl)propionamide;

N-{[3-bromo-4-(methyloxy)phenyl]methyl}-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinyl)propionamide;

N-[(3,5-dimethylphenyl)methyl]-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinyl)propionamide;

N-[(3,4-dibromophenyl)methyl]-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinyl)propionamide;

N-[(3-fluoro-2-methylphenyl)methyl]-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinyl)propionamide;

N-{[2-chloro-3-(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinyl)propionamide;

N-{-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluorophenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide;

N-[(3,5-dibromophenyl)methyl]-3-(4-fluorophenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide;

N-{-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(2,4-dichlorophenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide;

N-{-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluoro-2-methylphenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide;

N-[(3,5-dibromophenyl)methyl]-3-(4-fluoro-2-methylphenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide;

N-[(3,5-dibromophenyl)methyl]-3-(3,4-dichlorophenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide;

N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide;

3-(4-chlorophenyl)-*N*-[(3,5-dibromophenyl)methyl]-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide;

N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-*N*-methyl-3-(3-piperidinylidene)propionamide;

N-[(3,5-dibromophenyl)methyl]-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinylidene)propionamide;

N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluoro-2-methylphenyl)-*N*-methyl-3-(1,2,3,6-tetrahydro-4-pyridinyl)propionamide;

N-{(1*R*)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluoro-2-methylphenyl)-*N*-methyl-3-(1,2,3,6-tetrahydro-4-pyridinyl)propionamide;

N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-*N*-methyl-3-(3-pyrrolidinyl)propionamide;

N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-3-(3-fluoro-3-piperidinyl)-*N*-methylpropionamide;

N-{-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluorophenyl)-*N*-methyl-3-(2-morpholinyl)propionamide;

N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-*N*-methyl-3-(3-piperidinyl)propionamide;

N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-*N*-methyl-3-(4-pyridinyl)propionamide;

and enantiomers, diastereiosomers, pharmaceutically acceptable salts ~~(e.g hydrochloride)~~ and solvates thereof.

7. (Currently Amended) A compound selected from *N*-{(1*R*)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinyl)propionamide(diastereoisomer 1);

N-{(1*S*)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinyl)propionamide (diastereoisomer 2);

N-{(1*R*)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluorophenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide (diastereoisomer 1;

N-[(3,5-dibromophenyl)methyl]-3-(4-fluorophenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide (enantiomer 2);

N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-3-(3-fluoro-3-piperidinyl)-*N*-methylpropionamide (diastereoisomer A);

and pharmaceutically acceptable salts ~~(e.g hydrochloride)~~ and solvates thereof.

8. (Currently Amended) A process for the preparation of a compound as claimed in claim 1 which comprises reacting an activated derivative of the carboxylic acid of formula (II) wherein R_1 has the meaning previously defined or is a protected group thereof, with amine (III)



wherein R_2 is C_{1-4} alkyl or a nitrogen protecting group, followed where necessary by removal of any protecting group.

9-11. (Canceled)

12. (Currently Amended) A pharmaceutical composition comprising a compound as claimed in claim 1 ~~any claims 1 to 7~~ in admixture with one or more pharmaceutically acceptable carriers or excipients.

13. (Canceled)

14. (New) A compound as claimed in claim 1 wherein R is fluorine or chlorine or methyl and n is an integer from 1 to 2.

15. (New) A compound as claimed in claim 1 wherein R is fluorine or chlorine or methyl and n is an integer from 1 to 2; R_1 is piperidyl, 2-morpholinyl, 1,2,3,6-tetrahydro-4-pyridinyl, pyridyl or pyrrolidinyl and wherein R_1 is optionally substituted by one or two groups selected from fluorine, methyl or ethylC_{1-4} alkoxy; R_2 and R_3 are independently hydrogen or methyl; R_4 is hydrogen, methyl or together with R_3 is cyclopropyl and R_5 is trifluoromethyl, methyl, methoxy, bromine, chlorine or fluorine atom and m is preferably an integer from 1 to 2.

16. (New) A method for the treatment of a condition mediated by a tachykinin and/or selective inhibition of serotonin reuptake transporter protein in a mammal in need thereof, comprising administering an effective amount of a compound as claimed in claim 1.

17. (New) The method as claimed in claim 16, wherein said tachykinin is substance P.

18. (New) The method as claimed in claim 16, wherein said mammal is man.